Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 13/20 | 0.45 |
| ▸ | CDC25B | P30305 | 2/20 | 0.44 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209243 | 0.93 | ACLY (0.49) | ACLYCDC25BMAP3K8ADRA2AADRA2B | |
| Trifluoroacetic Acid SCHEMBL4213728 | 0.88 | ACLY (0.45) | ACLYCDC25BKDM4CKDM5B | |
| SCHEMBL4222846 | 0.85 | MAP3K8 (0.38) | ACLYCDC25BMAP3K8ADRA2AADRA2B | |
| Trifluoroacetic Acid SCHEMBL4218342 | 0.84 | CDC25B (0.42) | CDC25BTAS2R14ADRA2AADRA2BADRA2C | |
| SCHEMBL4226821 | 0.81 | KDM4C (0.50) | ACLYCDC25BKDM4CKDM5B | |
| Trifluoroacetic Acid SCHEMBL4225801 | 0.77 | PAX8 (0.47) | ACLYTAS2R14 | |
| SCHEMBL13890914 | 0.76 | KDM4C (0.46) | CDC25BADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4213733 | 0.74 | TRPV1 (0.45) | — | |
| Trifluoroacetic Acid SCHEMBL4218730 | 0.73 | TRPV1 (0.51) | KDM4C | |
| SCHEMBL4220149 | 0.72 | XDH (0.48) | MAP3K8TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | ACLY 430/4885CDC25B 3872/4885MAP3K8 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.